Key Sessions and Real-World Case Learning at PNS 2025: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc

Author(s):

Key Takeaways

The PNS Annual Meeting is the largest global event focused on peripheral nerve biology and medicine, scheduled for May 17-20 in Edinburgh, Scotland.
Recent advancements include gene therapies for Charcot-Marie-Tooth disease, immunomodulatory treatments, and targeted therapies like small molecules and CAR T-cell therapies.
The meeting will emphasize a shift from diagnostic research to treatment strategies, highlighting the convergence of basic science and clinical application.
Clinicians and scientists will exchange ideas, access unpublished data, and align clinical and scientific priorities for peripheral nerve disorders.

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting shared key sessions and trends clinicians should follow at the upcoming meeting, emphasizing collaboration, trial data, and clinical relevance. [WATCH TIME: 3 minutes]

WATCH TIME: 3 minutes

"Diseases don’t respect borders, so neither should our research community. That’s why global participation is essential to the success of this meeting."

The 2025 Peripheral Nerve Society (PNS) Annual Meeting, considered the largest scientific gathering focused on peripheral nerve biology and medicine, kicks off May 17^th and runs for 3 days, covering the latest in treatment advances and research. The event begins on Sunday with several special interest group sessions, mainly focused on Charcot-Marie-Tooth and related neuropathies, followed by a variety of different educational trainings. Within this education day, clinicians will be able to connect with others in the field, participate in panel discussions, and attend lunch with other experts.

In the ensuring day, the conference formally kicks off with opening remarks by president Claudia Sommer, MD, followed by notable lectures from Ted Price, PhD; Jun Li, MD, PhD; and Daniela Latorre, PhD. Other concurrent special interest group sessions will cover inflammatory neuropathies, traumatic toxic neuropathies, and neuropathic pain, among others. Throughout the meeting, there will be several industry sponsored symposiums, giving attendees the latest insights on drug development and emerging treatments impacting patients in the near future.

Ahead of the meeting, committee chairs Kathrin Doppler, MD, and Vincent Timmerman, PhD, MSc, highlighted the sessions clinicians should prioritize at the upcoming 2025 PNS Annual Meeting, including the Clinical Highlights and Clinical Case sessions—both designed to spotlight emerging trial data and real-world application. Doppler, a neurologist at the University Hospital of Wurzburg, in Germany, and Timmerman, a professor at the University of Antwerp, in Belgium, emphasized that this year’s program includes more content on treatment, outcome measures, and pathophysiology, with balanced offerings for both clinicians and researchers.

Click here for PNS 2025 coverage.